key: cord-0945041-5l3nxfg3
authors: Kleineberg, Nina N.; Knauss, Samuel; Gülke, Eileen; Pinnschmidt, Hans O.; Jakob, Carolin E. M.; Lingor, Paul; Hellwig, Kerstin; Berthele, Achim; Höglinger, Günter; Fink, Gereon R.; Endres, Matthias; Gerloff, Christian; Klein, Christine; Stecher, Melanie; Classen, Annika Y.; Rieg, Siegbert; Borgmann, Stefan; Hanses, Frank; Rüthrich, Maria M.; Hower, Martin; Tometten, Lukas; Haselberger, Martina; Piepel, Christiane; Merle, Uta; Dolff, Sebastian; Degenhardt, Christian; Jensen, Björn‐Erik O.; Vehreschild, Maria J. G. T.; Erber, Johanna; Franke, Christiana; Warnke, Clemens
title: Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)
date: 2021-09-03
journal: Eur J Neurol
DOI: 10.1111/ene.15072
sha: c274a0213f67243b1285c4c3208626344e5c3f44
doc_id: 945041
cord_uid: 5l3nxfg3

BACKGROUND AND PURPOSE: During acute coronavirus disease 2019 (COVID‐19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real‐world data from a multinational registry. METHODS: We analyzed COVID‐19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS‐Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression. RESULTS: A total of 6537 COVID‐19 patients (97.7% PCR‐confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short‐term outcome of COVID‐19. CONCLUSION: Our data on mostly hospitalized COVID‐19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short‐term outcome. ICB in critical COVID‐19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life‐threatening systemic viral infection.

SARS-CoV-2 can invade the nervous system, despite there being no clear evidence for CNS damage directly caused by the virus [5] .

The early neurological manifestations observed range from smell and taste dysfunction, dizziness, headache, myalgia, and impaired consciousness [2, 6] to severe neurological complications, such as cerebrovascular events or encephalopathy [7] [8] [9] [10] .

These neurological symptoms are likely to be of relevance for short-and long-term patient outcomes. Severe complications may be associated with increased early mortality [11] , while relatively mild symptoms may persist as part of a so-called "long-COVID" or "post-COVID-syndrome" in some patients. This may contribute to prolonged morbidity after recovery from the acute respiratory infection [10, [12] [13] [14] [15] . As such, prospective large-scale studies are warranted to clarify the relevance of neurological symptoms and complications of COVID-19. Studies on neurological manifestations related to disease outcome are complicated by the fact that several variables, e.g., older age, male sex, or cardiovascular morbidity, that are consistently associated with an increased risk of a more severe COVID-19 disease course [16, 17] , need to be considered as possible confounders. The same is true for neurological premorbidity that may affect the symptoms reported and COVID-19 outcome.

Furthermore, dementia or stroke were reported to be independently associated with COVID-19-related deaths in one study [18] . In contrast, others did not observe an increased risk of a more severe COVID-19 disease course in patients with Parkinson's disease or dementia [19] or multiple sclerosis [20, 21] .

Using data from the multinational, observational cohort of patients included in the Lean European Open Survey on SARS-Infected Patients (LEOSS) registry [16] , we aimed to characterize the occurrence and frequencies of neurological symptoms and complications reported during the acute phase of a SARS-CoV-2 infection and to determine the impact of these symptoms and complications, and prior neurological diseases on COVID-19 disease outcome.

In this observational study, we analyzed data on patients with confirmed SARS-CoV-2 infection included in LEOSS, with diagnosed infection between January 2020 and February 2021. Submission of patients' data into LEOSS was accessible for the approved 127 partner sites, i.e., physicians from hospitals, outpatient clinics and private practices across Europe involved in the treatment of COVID-19 patients. Data were recorded retrospectively and anonymously.

A dedicated form for neurological data items was developed by a working group of specialized neurologists across Germany and implemented in the registry. From this set, the following signs and symptoms were analyzed: impaired sense of smell and taste; nausea and emesis; muscle ache and weakness; delirium; excessive tiredness; headache; and meningism. Additionally, intracerebral bleeding (ICB), ischemic stroke, meningitis and encephalitis, seizures, critical illness myopathy (CIM) and critical illness polyneuropathy (CIP) were recorded as neurological manifestations and complications.

In LEOSS, data assessments are retrieved in different disease phases, namely, at baseline (timepoint of positive SARS-CoV-2 test result), in the uncomplicated (UC) phase, in the complicated (CO) phase, and in the critical (CR) phase (for phase definitions, see Figure 1 and Jakob et al. [16] ).

Descriptive analyses were performed for the entire cohort and for each of the clinical phases documented (UC, CO and CR phases). If a sign or symptom was neither reported nor the option "unknown" ticked in LEOSS, this may suggest that the symptom was absent or the data entry was incomplete. To account for reporting bias, we analyzed the F I G U R E 1 Definition of disease phases. GOT, glutamate-oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; qSOFA, quick sepsis-related organ failure assessment score descriptive data in respect to valid data entries of each of the items collected, explaining the different denominators for several of the items analyzed. The durations of the in-patient stay in the hospital, on the intensive care unit (ICU), and of the mechanical ventilation were calculated as median with interquartile range (IQR) and mean ± standard deviation (SD). The chi-squared test was used to associate anticoagulation, interventions, and laboratory results with the occurrence of ICB.

Two clinical endpoints were defined: (i) death during hospitalization (EP1) and (ii) a combined endpoint, death or a CR phase (defined as complicated or critical phase) or no recovery until last-known status (EP2). Relationships among potential explanatory variables for the outcome (age, sex, pre-existing diseases, such as asthma, pulmonary diseases, cardiovascular diseases, cerebrovascular diseases, neurodegenerative diseases, neuroimmunological diseases, and the signs and symptoms impaired sense of smell and taste, muscle aches and weakness, excessive tiredness, headache, delirium [ Table 4 ]) and the two endpoints were examined using nonlinear, categorical principal component analysis (CATPCA) [22] . Their associations were evaluated primarily based on their loadings on the first two dimensions extracted by the analysis. Before CATPCA and logistic regression analyses were performed, missing data were replaced by multiple imputations, using the fully conditional specification method and producing five imputed datasets. All variables involved in CATPCA and logistic regression served as independent variables for imputation, but missing data for the two endpoints were not imputed. Age categories were treated as a continuous variable. Univariable logistic regression analyses tested the effects of individual independent variables on EP1 and EP2 (Table S2 and Figure S1 ). The univariable model was further adjusted for age and sex. All independent variables were entered in a multivariable logistic regression model (initial full model).

Nonsignificant independent variables were then removed from the multivariable model following a stepwise-backward procedure. The level of significance was set at p < 0.05, two-sided. Statistical analyses were performed using SPSS version 27.

The study was approved by the local ethics committees, waiving the requirement for written informed consents for routine clinical data recorded anonymously. Please see Jakob et al. [16] for further information regarding ethical statements and trial registration of LEOSS, and for the anonymization procedure see Jakob et al. [23] .

We analyzed data from 6537 patients with SARS-CoV-2 infection, diagnosed between January 2020 and February 2021 (for monthly enrollment, see Table S1 ). Most patients were reported from German study sites (93.6%, 6295/6537), the diagnosis was PCR-confirmed in 97.7% (6197/6341) and 57.7% of the patients (3773/6537) were male. The majority of patients was between 46 

Commonly, excessive tiredness (28.0%, 1466/5240), headache Of the patients reaching the CO or CR disease phase (52.8%, 3451/6537), the most frequent and severe neurological complications were cerebrovascular events. ICB (2.2%, 57/2605) was more frequently observed than ischemic stroke (1.0%, 26/2578), peaking in the CR phase at 5.0% (51/1027; Table 2 ). Patients with ICB in the CR phase more frequently showed thrombocytopenia (p = 0.006) and an elevated activated partial thromboplastin time (aPPT; p = 0.033). In these patients, therapeutic anticoagulation, mostly heparin (leading to an elevated aPPT), as well as extracorporeal membrane oxygenation (ECMO) were associated with ICB (p < 0.01 and p < 0.0001, respectively; Table 3 ). (Table 2) . (Table 5 and Figure S1 ). Neurological symptoms "all phases" depicts the occurrence of a symptom in the entire cohort. The neurological complications in total (CO or CR phase) represent the sum score of the patients that underwent the CO or CR phase.

Further, a symptom in the respected disease phase (BL, or UC, CO or CR phase) or a neurological complication (CO, CR phase) is reported. In the presentation by phase, multiple entries of a patient in UC, CO, or CR phase are possible, when a patient underwent various disease phases in the longitudinal course.

Abbreviations: BL, baseline; CO, complicated phase; CR, critical; CIM, critical illness myopathy; CIP, critical illness polyneuropathy; UC, uncomplicated phase.

The present large-scale analysis from LEOSS, a European multinational registry-based cohort study, focused on neurological signs, symptoms and complications in predominantly hospitalized (92.1%) SARS-CoV-2-infected patients who were mostly enrolled from German study sites (92.6%).

Olfactory and gustatory dysfunction, which can also occur in the absence of respiratory symptoms and nasal congestion, is considered a rather specific feature of COVID-19 patients, and may suggest direct involvement of the nervous system [24] . The rate of impaired sense of smell (9.0%) and taste (12.8%) in our cohort fell into the lower range compared to other studies reporting a prevalence between 5% and 88% [6, 24, 25] . The fact that the LEOSS cohort consists of predominantly hospitalized patients (>90%) with a comparably severe disease course, and the recruitment of patients was mainly by physicians not specialized in neurology, may explain this finding, leading to underreporting of this rather mild, albeit specific symptom [16] . Olfactory and gustatory dysfunction had no impact on the early disease course. However, as these symptoms were consistently shown in previous studies to persist in a relevant proportion of patients far beyond recovery from the acute respiratory infection [12] [13] [14] , these symptoms may still cause prolonged morbidity and neurological sequelae in a subset of patients.

Most of the other neurological signs and symptoms reported at baseline in our study were non-specific, with a high prevalence of excessive to previously reported studies reporting strokes (range 1.1%-1.9%) [11, 29, 30] . In the present study, the occurrence of ischemic stroke increased with disease severity (CO phase: 0.5%; CR phase: 1.3%), possibly explained by the association of COVID-19 with coagulopathy [31] .

Interestingly, while in most previous studies ischemic strokes were more frequent than hemorrhagic strokes [6, [32] [33] [34] [35] , we found the opposite, with cerebral hemorrhages peaking in the CR phase (5.0%). This is probably explained by a higher frequency of interference with the blood coagulation system (Table 3) Pooled results from analyses on five imputed data sets. In the final multivariable model, only significant predictors (p < 0.05) were included.

Abbreviations: CI, confidence interval, d., diseases; OR, odds ratio.

are able to complain of headache at baseline, may be in a less severe medical condition, while patients at more severe disease stages may be unable to express this complaint. In line with these considerations and our findings, in a smaller cohort study of COVID-19 patients, there was a trend of headache being more frequently reported in the group without Acute Respiratory Distress Syndrome (ARDS) than with ARDS [42] .

Extending previous work, the present study shows that a preexisting neurodegenerative disease (comprising dementia, movement disorders, and motor neuron diseases) is an independent risk factor for mortality and a more severe COVID-19 disease course.

This finding persisted after adjusting for sex and age, and was consistently seen across the different age strata of the study. Indeed, patients with prior neurodegenerative diseases are at higher risk of reduced lung function and respiratory system-related complications, e.g., aspiration pneumonia due to dysphagia [43] . Therefore, a higher mortality rate and worse outcomes in patients with neurodegenerative diseases appear plausible and fit with the literature. One study reported a higher case fatality rate for patients with Parkinson's disease [44] . Another study in a cohort of 16, 749 patients hospitalized with COVID-19 reported that the combined prior conditions "dementia or stroke" were independently associated with COVID-19-related deaths [18] . Our study seems to contrast with a previous study [19] Formal analysis (equal); Methodology (equal); Project administration (lead); Supervision (lead); Writing -review and editing (lead).

The data are not publicly available due to privacy or ethical 

Hospital Passau (Julia Lanzster), Hospital Ingolstadt (Stefan Borgmann)

Practice at Ebertplatz (Christopf Wyen)

Municipal Hospital Karlsruhe (Christian Degenhardt), Maria Hilf Hospital (Hendrik Haake

Maltese Hospital St. Franziskus-Hospital Flensburg (Mile Milovanovic), MS Center Belgium (Marie D'Hooghe)

Agaplesion Diaconia Hospial Rotenburg (David Heigener)

Practice for general medicine Drs

Open Access funding enabled and organized by Projekt DEAL. WOA Institution: Uniklinik Koln Blended DEAL

Kleineberg: Conceptualization (lead); Formal analysis (lead)

Visualization (equal)

Samuel Knauss: Conceptualization (lead)

Software (supporting)

Visualization (equal)

Eileen Gülke: Conceptualization (lead)

Software (supporting)

Visualization (equal)

Writing -original draft (equal). Hans O. Pinnschmidt: Formal analysis (lead)

Data curation (lead); Project administration (equal). Paul Lingor: Writing -review and editing (supporting)

Melanie Stecher: Data curation (equal); Project administration (supporting)

Siegbert Rieg: Investigation (equal). Stefan Borgmann: Investigation (equal). Frank Hanses: Investigation (equal). Maria M. Rüthrich: Investigation (equal). Martin Hower: Investigation (equal). Lukas Tometten: Investigation (equal)

Johanna Erber: Investigation (lead); Writing -review and editing (equal). Christiana Franke: Conceptualization (lead)

Clemens Warnke: Conceptualization (lead)

Clinical characteristics of coronavirus disease 2019 in China

A systematic review of neurological symptoms and complications of COVID-19

Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study

Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Cerebrovascular events and outcomes in hospitalized patients with COVID-19: the SVIN COVID-19 Multinational Registry

Neurological manifestations of COVID-19" -guideline of the German society of neurology

EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic

Neuro-COVID-19 is more than anosmia: clinical presentation, neurodiagnostics, therapies, and prognosis

A prospective study of neurologic disorders in hospitalized COVID-19 patients in New York City

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

Persistent symptoms in patients after acute COVID-19

Sixtyday outcomes among patients hospitalized with COVID-19

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)

Risk factors of the severity of COVID-19: a meta-analysis

Factors associated with COVID-19-related death using OpenSAFELY

Outcomes of SARS-CoV-2 infections in patients with neurodegenerative diseases in the LEOSS Cohort

Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies. a review of 873 published cases

COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response

Nonlinear principal components analysis with CATPCA: a tutorial

Design and evaluation of a data anonymization pipeline to promote Open Science on COVID-19. Scientific data

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

COVID-19, nausea, and vomiting

New onset neurologic events in people with COVID-19 in 3 regions in China

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

The unique characteristics of COVID-19 coagulopathy

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome

Acute cerebrovascular events in hospitalized COVID-19 patients

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Hemorrhagic stroke in setting of severe COVID-19 infection requiring Extracorporeal Membrane Oxygenation (ECMO)

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

Cerebrospinal fluid confirmed COVID-19-associated encephalitis treated successfully

Clinical, radiological, and molecular findings of acute encephalitis in a COVID-19 patient: a rare case report

Cerebrospinal fluid features in patients with coronavirus disease 2019 and neurological manifestations: correlation with brain magnetic resonance imaging findings in 58 patients

Cerebrospinal fluid in COVID-19: a systematic review of the literature

Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients

Dysphagia: current reality and scope of the problem

Coronavirus disease 2019 case fatality and Parkinson's disease

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

Clinical characteristics and outcomes in patients with Coronavirus disease 2019 and multiple sclerosis

COVID-19 in multiple sclerosis patients and risk factors for severe infection